Skip to main content
EVO
NASDAQ Life Sciences

Goldman Sachs Group Significantly Increases Stake in Evotec SE to 6.12%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.43
Mkt Cap
$1.24B
52W Low
$2.84
52W High
$4.8
52W Position info
21% above low
Off High info
29% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

EVO sits 21% above its 52-week low of $2.84 on light trading volume (0.1× avg).

Summary

Goldman Sachs Group reported increasing its total stake in Evotec SE to 6.12% through instruments, signaling increased institutional interest, while MAK Capital also raised its holdings.


Key Events · Ownership and Investor Activity · EVO

  • Goldman Sachs Increases Holdings

    The Goldman Sachs Group, Inc. reported increasing its total stake in Evotec SE to 6.12% as of January 13, 2026, primarily through instruments. This represents a 2.44% increase from its position on January 9, valued at approximately $14.89 million.

  • MAK Capital Increases Holdings

    Michael Kaufman and MAK Capital Fund LP increased their combined stake in Evotec SE to 5.17% as of January 9, 2026, primarily through direct shareholdings. This is a net increase of 0.14% from their previous position, valued at approximately $0.85 million.

  • Prior Goldman Sachs Reduction

    On January 9, 2026, Goldman Sachs had reported a temporary reduction in its total stake to 3.68% from a previous 5.27%, valued at approximately $8.66 million.


Analysis · EVO · Life Sciences

The filing indicates a notable increase in institutional ownership for Evotec SE. The Goldman Sachs Group, Inc. reported a significant increase in its total stake to 6.12% as of January 13, 2026, primarily through instruments. This latest move represents a substantial acquisition, following a temporary reduction earlier in January, and suggests renewed and stronger institutional confidence in the company. Additionally, Michael Kaufman and MAK Capital Fund LP also increased their combined stake to 5.17% on January 9, further contributing to a positive investor sentiment regarding the company's ownership structure.

At the time of this filing, EVO was trading at $3.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.84 to $4.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EVO - Latest Insights

EVO
Jul 13, 2026, 3:43 PM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $2.34
Real-time Price: $1.95 info
Change: -$0.390 (-17%) info
Market Cap: $708.994M info
EVO
Jun 30, 2026, 1:01 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.80
Real-time Price: $1.95 info
Change: -$0.845 (-30%) info
Market Cap: $708.994M info
EVO
Jun 17, 2026, 6:02 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.76
Real-time Price: $1.95 info
Change: -$0.810 (-29%) info
Market Cap: $708.994M info
EVO
May 12, 2026, 5:15 PM EDT
Source: Access Newswire
Importance Score:
8
Price at Filing: $3.00
Real-time Price: $1.95 info
Change: -$1.05 (-35%) info
Market Cap: $708.994M info
EVO
May 06, 2026, 9:39 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.11
Real-time Price: $1.95 info
Change: -$1.16 (-37%) info
Market Cap: $708.994M info